News & Events about Intercept Pharmaceuticals Inc.
Globe Newswire
3 months ago
Planned interim analysis from the first of two Phase 2 studies shows combination of OCA 5-10 mg + bezafibrate 400 mg normalized a range of biomarkers of PBC (ALP, total bilirubin, GGT, ALT and AST) in 58% of patients at 12 weeks ALP normalized in 75% of patients in the OCA 5-10 mg + bezafibrate 400 ...
Thinking about buying stock in SoundHound AI, Virios Therapeutics, Locafy, Intercept Pharmaceuticals, or D-Wave Quantum? Thinking about buying stock in SoundHound AI, Virios Therapeutics, Locafy, Intercept Pharmaceuticals, or D-Wave Quantum? PR Newswire NEW YORK, June 23, 2023 NEW YORK, June 23...
Globe Newswire
3 months ago
Measures reinforce Companys ability to drive growth in PBC business and continue developing innovative new medicines Company to discontinue all NASH-related investment and reduce workforce by approximately one third Company anticipates achieving profitability in 2024R&D investment prioritized on ...
Globe Newswire
3 months ago
NEW YORK, June 17, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. (Intercept or the Company) (NASDAQ:ICPT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The ...
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT Get Rating) B. Riley raised their FY2023 earnings estimates for shares of Intercept Pharmaceuticals in a report issued on Monday, April 24th. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will earn $0.19 per share for the ...